Mitsubishi UFJ Asset Management Co. Ltd. Increases Stake in AbbVie Inc. $ABBV

Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in AbbVie Inc. (NYSE:ABBV) by 4.5% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,569,082 shares of the company’s stock after acquiring an additional 154,057 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd. owned about 0.20% of AbbVie worth $826,385,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. raised its position in AbbVie by 0.3% in the 3rd quarter. Vanguard Group Inc. now owns 177,747,261 shares of the company’s stock worth $41,155,601,000 after buying an additional 448,554 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of AbbVie by 2.4% in the second quarter. Geode Capital Management LLC now owns 39,178,351 shares of the company’s stock worth $7,240,169,000 after purchasing an additional 924,761 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in AbbVie by 6.0% during the second quarter. Charles Schwab Investment Management Inc. now owns 26,783,329 shares of the company’s stock valued at $4,970,848,000 after purchasing an additional 1,517,222 shares in the last quarter. Norges Bank bought a new stake in AbbVie during the second quarter worth approximately $4,288,200,000. Finally, Raymond James Financial Inc. lifted its holdings in shares of AbbVie by 41.8% in the 2nd quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock worth $1,733,222,000 after acquiring an additional 2,753,312 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Stock Down 0.6%

Shares of NYSE:ABBV opened at $227.01 on Thursday. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81. The company has a 50-day moving average price of $224.22 and a 200 day moving average price of $222.70. The company has a market cap of $401.38 billion, a P/E ratio of 96.19, a PEG ratio of 0.79 and a beta of 0.35.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. The business had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The business’s revenue was up 10.0% on a year-over-year basis. During the same period last year, the business earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a yield of 3.0%. AbbVie’s dividend payout ratio (DPR) is presently 293.22%.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. JPMorgan Chase & Co. increased their target price on shares of AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a report on Monday, November 3rd. BMO Capital Markets reiterated an “outperform” rating and set a $258.00 price target on shares of AbbVie in a research report on Thursday, January 15th. Royal Bank Of Canada initiated coverage on AbbVie in a research report on Tuesday. They issued an “outperform” rating and a $260.00 price objective on the stock. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $223.00 price objective on shares of AbbVie in a report on Wednesday, January 28th. Finally, Piper Sandler increased their target price on AbbVie from $289.00 to $299.00 and gave the company an “overweight” rating in a report on Wednesday, February 18th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and an average target price of $253.15.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie announced a $380 million investment to build two new API (active pharmaceutical ingredient) manufacturing facilities at its North Chicago campus — a multi‑year project expected to boost U.S. supply security, support production for obesity and other franchises, and create several hundred jobs (facilities targeted to be operational by 2029). AbbVie to build 2 API plants in Illinois
• Positive Sentiment: The FDA approved the VENCLEXTA (venetoclax) + acalabrutinib combination for first‑line treatment of CLL — the first all‑oral, fixed‑duration regimen for previously untreated patients, which should expand market opportunity and support oncology revenue growth. FDA Approves AbbVie (ABBV) VENCLEXTA and Acalabrutinib Combination for First-Line CLL
• Positive Sentiment: Barclays initiated coverage with an Overweight rating and a $275 price target, citing upside from operating leverage and under‑appreciated growth potential — a note that can improve sentiment among institutional investors. Barclays Initiates AbbVie (ABBV) with Overweight Rating on Growth Potential
• Neutral Sentiment: AbbVie completed a real‑world study of Vraylar in Bipolar I disorder — supportive real‑world evidence can aid uptake, but the near‑term revenue impact is limited. AbbVie’s Real‑World Vraylar Study in Bipolar I Disorder Reaches Completion
• Neutral Sentiment: AbbVie will present at the TD Cowen Health Care Conference on March 3 — a routine investor event that could provide incremental disclosure but not guaranteed news. AbbVie to Present at the TD Cowen 46th Annual Health Care Conference
• Neutral Sentiment: Multiple retail and dividend‑oriented writeups are highlighting AbbVie’s high yield and growing payout — this supports income‑investor interest but is unlikely to move the stock materially on its own. This High‑Yield Pharma Beast AbbVie Could Turn Dividends Into Life‑Changing Income
• Negative Sentiment: Analysts and research notes flag execution risk and intensifying competition across parts of AbbVie’s pipeline and immunology portfolio — these concerns are constraining upside in some models and tempering investor enthusiasm. How Pipeline Shifts And Competition Are Reshaping The AbbVie (ABBV) Investment Narrative
• Negative Sentiment: Valuation and momentum considerations (ABBV trades with a high P/E and recently near its 52‑week range) plus below‑average intraday volume can prompt profit‑taking even when company news is constructive.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.